BAK-loss lethal prostate cancer: uncovering therapeutic vulnerabilities to deliver new treatments and improve clinical outcomes

Federal Project Grant Award Summary

The Defense Health Agency (DHA) awarded $749,996 to the Institute of Cancer Research: Royal Cancer Hospital (The) on August 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) for the project "BAK-LOSS Lethal Prostate Cancer: Uncovering Therapeutic Vulnerabilities to Deliver New Treatments and Improve Clinical Outcomes." The four-year award, extending through July 31, 2029, supports research conducted in Great Britain, United Kingdom, aimed at identifying and exploiting therapeutic vulnerabilities in lethal prostate cancer to develop novel treatment approaches and enhance clinical outcomes for military service members and the general public.

The research initiative will deliver translational and basic biomedical research services focused on prostate cancer therapeutics and drug development. The project involves hypothesis-driven investigations designed to characterize molecular mechanisms of lethal prostate cancer, identify biomarkers, and develop innovative therapeutic strategies. As a frequently awarded international research institution with established partnerships across prominent U.S. medical centers, the Institute will contribute to the DHA's broader portfolio of oncology research through cutting-edge scientific findings and therapeutic innovations that advance military health priorities and public health objectives consistent with the Military Medical Research and Development program's mission to transform healthcare through impactful biomedical research.